



ORIGINAL ARTICLE

Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002–2012

Dragana Radovanovic,¹ Burkhardt Seifert,² Philip Urban,³ Franz R Eberli,⁴ Hans Rickli,⁵ Osmund Bertel,⁶ Milo A Puhan,² Paul Erne,⁷ on behalf of the AMIS Plus Investigators

¹AMIS Plus Data Center, Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland

²Division of Biostatistics, Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland

³Cardiovascular Department, Hôpital de La Tour, Geneva, Switzerland

⁴Division of Cardiology, Stadtspital Triemli, Zurich, Switzerland

⁵Division of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland

⁶Cardiology Centre, Klinik Im Park, Zurich, Switzerland

⁷Department of Cardiology, Luzerner Kantonsspital Luzern, Lucerne, Switzerland

Correspondence to

Dr Dragana Radovanovic, AMIS Plus Data Center, Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben 84, Zurich 8001, Switzerland; dragana.radovanovic@uzh.ch

Published Online First
1 November 2013



► <http://dx.doi.org/10.1136/heartjnl-2013-305104>

To cite: Radovanovic D, Seifert B, Urban P, *et al.* *Heart* 2014;**100**:288–294.

ABSTRACT

Objective This study aimed to assess the impact of individual comorbid conditions as well as the weight assignment, predictive properties and discriminating power of the Charlson Comorbidity Index (CCI) on outcome in patients with acute coronary syndrome (ACS).

Methods A prospective multicentre observational study (AMIS Plus Registry) from 69 Swiss hospitals with 29 620 ACS patients enrolled from 2002 to 2012. The main outcome measures were in-hospital and 1-year follow-up mortality.

Results Of the patients, 27% were female (age 72.1 ±12.6 years) and 73% were male (64.2±12.9 years). 46.8% had comorbidities and they were less likely to receive guideline-recommended drug therapy and reperfusion. Heart failure (adjusted OR 1.88; 95% CI 1.57 to 2.25), metastatic tumours (OR 2.25; 95% CI 1.60 to 3.19), renal diseases (OR 1.84; 95% CI 1.60 to 2.11) and diabetes (OR 1.35; 95% CI 1.19 to 1.54) were strong predictors of in-hospital mortality. In this population, CCI weighted the history of prior myocardial infarction higher (1 instead of -0.4, 95% CI -1.2 to 0.3 points) but heart failure (1 instead of 3.7, 95% CI 2.6 to 4.7) and renal disease (2 instead of 3.5, 95% CI 2.7 to 4.4) lower than the benchmark, where all comorbidities, age and gender were used as predictors. However, the model with CCI and age has an identical discrimination to this benchmark (areas under the receiver operating characteristic curves were both 0.76).

Conclusions Comorbidities greatly influenced clinical presentation, therapies received and the outcome of patients admitted with ACS. Heart failure, diabetes, renal disease or metastatic tumours had a major impact on mortality. CCI seems to be an appropriate prognostic indicator for in-hospital and 1-year outcomes in ACS patients.

ClinicalTrials.gov Identifier NCT01305785

INTRODUCTION

Chronic comorbidities are frequently encountered in patients presenting with acute coronary syndrome (ACS) and have a high impact on patient outcome.^{1–5} The Charlson Comorbidity Index (CCI) provides a way of quantifying this impact in terms of survival and is also used as a prognostic comorbidity index in ACS populations.^{6–10} Indices, such as CCI, are useful for estimating the prognosis of real-world patients with comorbidities. Although changes of

management in ACS based on randomised controlled trials (RCT) have profoundly improved outcome, patients with comorbidities are still excluded from RCTs.⁶ To further improve treatment strategies, better knowledge of the impact of comorbidities is necessary. CCI may be an efficient way to capture the burden of comorbidities and study effect modification of current ACS treatments by comorbidities.¹¹

CCI was developed empirically 26 years ago as a prognostic index of comorbid conditions for patients admitted to a general medical service with a variety of medical conditions which, alone or in combination, might alter the risk of short-term mortality for patients enrolled in longitudinal studies.¹² The comorbidities were weighted by Charlson *et al* using a point system. One point was assigned to: past history of myocardial infarction (MI), heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic lung disease, connective tissue disease, peptic ulcer disease, mild liver disease and diabetes. The comorbidities weighted with 2 points were: diabetes with target organ damage, hemiplegia, moderate to severe renal disease, malignant neoplasm, leukaemia and lymphoma. Moderate to severe liver disease was weighted with 3 points and metastatic solid tumour and AIDS (stage C) were weighted with 6 points. Therefore, patients without comorbidities had CCI0, those with only one comorbidity weighted as 1 had CCI1, patients with 2 comorbidities where both were weighted 1 or one comorbidity was weighted 2 had CCI2, and the patients in which the sum of the weighted points of comorbidities was 3 or above had CCI≥3.

Using the data of 55 929 patients from six countries, Quan *et al*¹³ suggested that the weight assignment should be updated. However, CCI has not seen much validation in patients with ACS. Discrimination and calibration of CCI in ACS patients are not well known.

Therefore, the aim of this study was to assess the impact of CCI on clinical presentation, therapy received, the predictive properties of CCI in a large population of ACS patients and to see if changes of the CCI weight assignment are indeed necessary.

METHODS

The AMIS Plus project is an ongoing nationwide prospective registry of patients admitted with ACS to hospitals in Switzerland. It was founded in 1997

with the goal to understand the transfer, use and practicability of knowledge gained from randomised trials, and to generate data for the planning of subsequent prospective and randomised studies. Details have been previously published.^{14–18} From 106 hospitals treating ACS in Switzerland, 82 hospitals temporarily or continuously enrolled patients in AMIS Plus. Participating centres, ranging from community institutions to large tertiary facilities, provide blinded data for each patient through standardised internet-based or paper-based questionnaires. Participating centres are strongly encouraged to enrol all patients fulfilling the inclusion criteria to avoid selection bias. Hospital data are provided and completed by the treating physician or a trained study nurse. All data are checked for completeness, plausibility and consistency by the AMIS Plus Data Center in the Institute of Social and Preventive Medicine at the University of Zurich and treating physicians or study nurses are queried when necessary. The registry was approved by the Supra-Regional Ethics Committee for Clinical Studies, the Swiss Board for Data Security and the Cantonal Ethics Commissions. The AMIS Plus project is officially supported by the Swiss Societies of Cardiology, Internal Medicine and Intensive Care Medicine.

Comorbidities of the patients were assessed using CCI,¹² a scoring system which involves weighting factors on the basis of the number and severity of the diseases that was developed as a prognostic indicator for patients admitted to a general medical service with a variety of medical conditions. CCI used 1-year mortality of the primary study population to test the ability to predict risk of death from comorbidities. It showed that with each increased level of CCI, there were stepwise increases in the cumulative mortality attributable to comorbidities. When CCI was developed, the relative risks for 1-year mortality were used to assign weights to the different comorbidities: Those with a relative risk below 1.5 were assigned a weight of 1; conditions with a risk of 1.5 to <2.5 a weight of 2; conditions with a risk of $\geq 2.5 < 3.5$ a weight of 3; and metastatic tumours and AIDS were assigned a weight of 6. To simplify the system, the conditions with a relative risk below 1.2 were dropped. Finally, the relative risk per point was 1.39. In a validation cohort, the ability of CCI for 10-year mortality was analysed. There, the relative risk was 2.3 per point of CCI and 2.4 for each decade of life over the age of 50 years.¹²

The original definitions of the comorbid diseases from CCI were used in this study.¹² Data on the presence of the comorbidities were obtained from the patients' medical history charts, clinical and/or laboratory findings recorded by the treating physicians.

For the present analysis, the primary outcome measure was in-hospital mortality and the secondary outcome measure was 1-year mortality after discharge.

Patient selection

The present analysis included all ACS patients enrolled in AMIS Plus between January 2002 and September 2012. ACS included acute MI, defined according to the universal definitions of MI¹⁹ by characteristic symptoms and/or ECG changes and cardiac marker elevation (either creatine kinase MB fraction at least twice the upper limit of normal, or troponin I or T above individual hospital cut-off levels for MI), and unstable angina (symptoms or ECG changes compatible with ACS and cardiac marker levels lower than cut-off or normal levels).

Statistical analysis

The results are presented as percentages for categorical variables, and continuous variables are expressed as means \pm 1 SD. The

predictive properties of CCI were evaluated in three ways: First, a logistic regression model with in-hospital mortality as a dependent variable and the comorbidities of CCI, age and gender as independent variables were computed as the benchmark. Model fit of logistic regressions was assessed using the Hosmer–Lemeshow test. ORs were presented with 95% CIs (95% CI). AIDS could not be included in this analysis because there was no hospital death in patients with AIDS. To compare the results of this benchmark with the points of the CCI, the regression coefficients were scaled such that the sum is 31. The benchmark points of a patient then are the sum of scaled regression coefficients of his comorbidities. A patient with all comorbidities would hence get 31 points as is the case for CCI. The points from this regression analysis are reported with 95% CI obtained by scaling the CI for the corresponding regression coefficient.

Second, a receiver operating characteristic (ROC) curve was used to assess the discriminating ability of CCI alone and together with age in relation to the benchmark above. Third, calibration of CCI was analysed by comparing predicted and observed in-hospital and follow-up mortality in a logistic regression with CCI and age as predictors. To assess sensitivity of the result, the analyses were repeated separately for patients with and without prior MI.

To assess CCI as an independent predictor of in-hospital mortality, an additional multivariate logistic regression analysis included, besides age and gender, Killip class, the type of ACS, drug therapies received (aspirin, P2Y12 blockers (clopidogrel, prasugrel, or ticagrelor), β blocker, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), statin), and percutaneous coronary intervention.

All analyses were performed using IBM SPSS Statistics (V.20, SPSS, Chicago, Illinois, USA).

RESULTS

Between 2002 and 2012, 30 711 patients with ACS from 69 Swiss hospitals were enrolled in the AMIS Plus registry. Comorbidities were unknown for 1091 (3.6%) patients. Complete data on comorbidities were available from 29 620 patients. Among these patients, 27% were women (mean age 72.1 ± 12.6 years) and 73% were men (64.2 ± 12.9 years), and 46.8% had comorbidities. The frequencies of comorbidities in ACS patients are shown in table 1. Past history of MI was the most frequent comorbidity (18.0%) followed by diabetes mellitus (14.7%), moderate to severe renal disease (7.1%), cerebrovascular disease (6.0%) and chronic lung disease (6.0%).

More than half the patients (53.2%) had no comorbidities (CCI0), 22.6% of the patients had comorbidities weighted with 1 point (CCI1), 11.3% with 2 points (CCI2), and 12.9% of the patients were weighted with 3 points and above (CCI \geq 3). Baseline characteristics and therapy according to CCI are shown in table 2.

Impact of a single comorbidity on in-hospital mortality

Table 3 shows the ORs of in-hospital mortality for the individual comorbidities. The strongest age and gender-adjusted predictors of in-hospital mortality for ACS patients were heart failure (adjusted OR 1.88; 95% CI 1.57 to 2.25), metastatic tumours (OR 2.25; 95% CI 1.60 to 3.19), renal diseases (OR 1.84; 95% CI 1.60 to 2.11) and diabetes (OR 1.35; 95% CI 1.19 to 1.54).

Impact of the weighted comorbidities on in-hospital mortality

CCIs were independent in-hospital mortality predictors even after adjusting for baseline characteristics and the therapies

Table 1 Frequency of the comorbidities in patients hospitalised with acute coronary syndrome between 2002 and 2012 (n=29 620)

Comorbidities	Number of patients	Percentage of population
Past history of myocardial infarction	5324	18.0
Heart failure	1075	3.6
Peripheral vascular disease	1591	5.4
Cerebrovascular disease	1776	6.0
Dementia	582	2.0
Chronic lung disease	1778	6.0
Connective tissue disease	361	1.2
Peptic ulcer disease	665	2.2
Mild liver disease	227	0.8
Diabetes	4359	14.7
Diabetes with target organ damage	1069	3.6
Hemiplegia	210	0.7
Moderate to severe renal disease	2101	7.1
Malignant neoplasm	1269	4.3
Leukaemia	92	0.3
Lymphoma	139	0.5
Moderate to severe liver disease	170	0.6
Metastatic solid tumour	268	0.9
AIDS (stage C)	47	0.2

received: CCI1 had an OR of 1.36 (95% CI 1.16 to 1.60); $p=0.001$, CCI2 was 1.65 (95% CI 1.38 to 1.97); $p<0.001$ and CCI ≥ 3 had an OR of 2.20 (95% CI 1.86 to 2.57); $p<0.001$.

The cause of in-hospital death was cardiac in 1238 (78.3%) patients and non-cardiac in 344 (21.7%) patients.

Validity of CCI

ROC curve analysis (figure 1) demonstrates that predictive ability for in-hospital mortality of CCI together with age is superior to that of CCI alone. Age adjusted OR was 1.21 (95% CI 1.18 to 1.23) per point of CCI. For each additional 10 years of age, the OR was 1.91 (95% CI 1.82 to 2.00). Model fit was good (figure 2A) except for the patients below 50 years of age (Hosmer–Lemeshow $p<0.001$ for all patients, and $p=0.74$ for patients above 50 years of age).

CCI weighted the history of prior MI higher (1 instead of -0.4 , 95% CI -1.2 to 0.3 points), but heart failure (1 instead of 3.7, 95% CI 2.6 to 4.7) and renal disease (2 instead of 3.5, 95% CI 2.7 to 4.4) lower than was the case with independent predictors for mortality. Comparing logistic regression using CCI and age as predictors with the benchmark from table 3, ROC analyses showed that the prediction was equivalent; the areas under the ROC curves were both 0.76 (figure 1).

Discrimination and model fit were similar for patients with and without prior MI—areas under the curve were 0.74 and 0.76, and the p values of the Hosmer–Lemeshow test for patients above 50 years of age were 0.37 and 0.95, respectively.

Impact of CCI on 1-year follow-up mortality

Since 2005, a subgroup of 7066 ACS patients were followed for a median of 386 days (IQR 370, 409 days) after the event. From the followed patients, 57.7% had CCI0 (no comorbidities), 21.2% had CCI1, 10.5% CCI2 and 10.5% CCI3 or above. Age adjusted OR was 1.44 (95% CI 1.36 to 1.53) for follow-up mortality per CCI point. For each additional 10 years of age, the OR was 2.08 (95% CI 1.81 to 2.39). Area under the ROC

curve was 0.83, 95% CI 0.80 to 0.86. Model fit was good (figure 2B, Hosmer–Lemeshow $p=0.57$).

DISCUSSION

Our study showed that comorbidities, such as heart failure, diabetes, renal disease or metastatic tumours had a major impact on outcomes in patients hospitalised with ACS and confirmed previous studies that chronic comorbidities are frequently encountered in patients admitted for ACS in daily clinical practice.

The baseline characteristics of the ACS patients differed significantly between the CCI groups and in particular between those with no comorbidities (CCI0) and those patients with CCI1–CCI ≥ 3 , as clearly demonstrated by the risk factors hypertension, dyslipidemia and obesity. However, the proportion of current smokers was highest in the CCI0 group but steadily decreased the higher the weighted CCI. The higher the CCI, the longer the delay between symptom onset and admission, symptoms were less typical, there was a higher degree of haemodynamic instability (higher Killip class) and more frequent NSTEMI/UA compared with the patients with lower rates of comorbidities. ACS patients with comorbidities more frequently presented with cardiogenic shock, but were less frequently resuscitated before admission.

Furthermore, patients with comorbidities were less likely to receive guideline-recommended drugs (such as aspirin, P2Y12 blockers, β blocker, ACEI/ARB or statin) within the first 24 h after admission, as well as reperfusion therapy especially in the case of STEMI patients. These results confirm the findings from an earlier study using AMIS Plus data.⁹

Most comorbidities included in CCI had a significant impact on outcome in this population. From 17 comorbid conditions, after adjusting for age and gender, nine were independent indicators of in-hospital mortality (heart failure, peripheral vascular disease, cerebrovascular disease, hemiplegia, diabetes, liver and renal diseases, malignant neoplasm and metastatic tumours; table 3). The strongest predictors of in-hospital mortality of ACS patients in our population were heart failure, metastatic tumours, renal diseases and diabetes. These results are in line with those reported by Palau *et al*²¹ who showed that renal disease and heart failure (besides dementia, peripheral artery disease and prior MI) were important comorbidities for ACS patients.

Our study showed CCI groups above zero were independent predictors of in-hospital mortality even after adjustment for the type of ACS and therapy received. In-hospital as well as 1-year follow-up mortality rose with increasing CCI scores.

The original CCI was based on the 1-year mortality from an inception cohort study of 604 patients admitted to a general medical centre during 1 month and tested for its ability to predict risk of in-hospital and 10-year mortality from comorbidity diseases in a second cohort of 685 patients treated for primary breast cancer.¹² The results showed that among all the clinical and demographic variables, only two were significant predictors of risk of comorbid death—age and comorbidity. CCI was validated in several studies including patients with AMI,²² stable coronary artery disease,⁶ ischaemic stroke,⁷ as well as peritoneal dialysis patients⁸ and a Medicare population aged 65 years or older.²³

The influence of CCI on in-hospital and 1-year follow-up mortality was lower, as was the case in the original work of Charlson *et al*.¹²

Comorbidities could have different impacts on all-cause mortality in patients depending on the main diagnosis leading to

Table 2 Baseline characteristics and immediate therapy in patients admitted with acute coronary syndrome according to the Charlson Comorbidity Index

	CCI=0	CCI=1	CCI=2	CCI≥3	p Values
Patients, n (%)	15 754	6708	3334	3824	
Male gender (%)	11 896/15 754 (75.5)	4815/6708 (71.8)	2237/3334 (67.1)	2638/13 824 (69.0)	<0.001
Mean age (SD), years	62.3 (12.9)	67.9 (12.6)	72.2 (11.9)	74.9 (10.9)	<0.001
History of CAD (%)	3194/15 618 (20.5)	3437/6633 (51.8)	1843/3278 (56.2)	2451/3753 (65.3)	<0.001
Hypertension (%)	7357/14 969 (49.1)	4515/6378 (70.8)	2475/3181 (77.8)	3009/3664 (82.1)	<0.001
Dyslipidemia (%)	7064/13 998 (50.5)	3823/5929 (64.5)	1923/2926 (65.7)	2155/3283 (65.6)	<0.001
Smoking (current) (%)	6579/14 760 (44.6)	2035/6106 (33.3)	789/2956 (26.7)	801/3316 (24.2)	<0.001
Obesity (BMI≥30 kg/m ²) (%)	2457/13 509 (18.2)	1308/5622 (23.3)	642/2766 (23.2)	709/3127 (22.7)	<0.001
Time between symptom onset and admission in min (IQR 25 to 75)	215 (108, 610)	225 (110, 620)	233 (119, 669)	265 (120, 730)	<0.001
Resuscitation prior to admission (%)	689/15 649 (4.5)	265/6679 (3.8)	117/3351 (3.5)	118/3800 (3.1)	<0.001
Clinical presentation					
Typical symptoms (%)	10 416/11 790 (88.3)	4148/4870 (85.2)	1997/2459 (81.2)	2130/2851 (74.7)	<0.001
Chest pain (%)	13 356/15 406 (86.7)	5421/6550 (82.8)	2606/3217 (81.0)	2757 (74.3)	<0.001
Dyspnea (%)	3279/14 349 (22.9)	1925/6139 (31.4)	1166/3047 (38.3)	1733/3560 (48.7)	<0.001
Killip class (n patients)	15 671	6677	3318	3805	<0.001
Killip class I (%)	13 808(88.1)	5286 (79.2)	2339 (70.5)	2202 (57.9)	
Killip class II (%)	1234 (7.9)	954 (14.3)	651(19.6)	1058 (27.8)	
Killip class III (%)	236 (1.5)	233 (3.5)	213 (6.4)	388 (10.2)	
Killip class IV (%)	393 (2.5)	204 (3.1)	115 (3.5)	157 (4.1)	
ACS (n patients)	15 754	6708	3334	3824	<0.001
STEMI (%)	9480 (60.2)	3453 (51.5)	1538 (46.1)	1690 (44.2)	
NSTEMI (%)	5443 (34.5)	2716 (40.5)	1519 (45.6)	1929 (47.8)	
UA (%)	831 (5.3)	539 (8.0)	277 (8.3)	305 (8.0)	
Peak creatine kinase IU/L (mean median (IQR 25 to 75))	1204 (247, 1938)	883 (171, 1372)	735 (400, 1154)	631 (360, 946)	<0.001
Multivessel diseases (%)	5703/10 683 (53.4)	2755/4065 (67.8)	1248/1802 (69.3)	1272/1663 (76.5)	<0.001
Immediate therapy					
Aspirin (%)	15 219/15 705 (96.9)	6292/6681 (94.2)	3083/3321 (92.8)	3369/3805 (88.5)	<0.001
P2Y12 blocker (%)*	12 746/15 669 (81.3)	5030/6662 (75.5)	2216/3307 (67.0)	2245/3791 (59.2)	<0.001
GPIIb/IIIa inhibitors (%)	5243/15 438 (34.0)	1755/6581 (26.7)	699/3265 (21.4)	561/3745 (15.0)	<0.001
Heparin† (%)	13 979/15 639 (89.4)	5734/6658 (86.1)	2799/3303 (84.7)	3054/3791 (80.6)	<0.001
β blocker (%)	10 395/15 571 (66.8)	4416/6631 (66.6)	2147/3304 (65.0)	2296/3779 (60.8)	<0.001
Statin (%)	12 222/15 603 (78.3)	4955/6645 (74.6)	2333/3778 (64.6)	2441/3778 (64.6)	<0.001
ACEI/ARB (%)	7841/15 564 (50.4)	3583/6632 (54.0)	1839/3303 (55.7)	2022/3786 (53.4)	<0.001
Any PCI (%)	13 241/15 752 (84.1)	5047/6708 (75.2)	2145/3334 (64.3)	1874/3824 (49.0)	<0.001
Reperfusion in STEMI patients	9480	3453	1538	1690	
Thrombolysis (%)	681 (7.2)	199 (5.8)	68 (4.4)	48 (2.8)	<0.001
Primary PCI (%)	7496 (79.1)	2434 (70.5)	928 (60.3)	794 (47.0)	<0.001

*P2Y12 blockers: clopidogrel, prasugrel or ticagrelor.

†heparins, unfractionated heparin or low molecular weight heparin.

ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CCI, Charlson Comorbidity Index; BMI, Body Mass Index; PCI, percutaneous coronary intervention.

hospital admission. Thus, despite a relative weight of 6, AIDS had no impact on mortality in our patients. The original CCI includes diseases which are also reflected in the population being evaluated.

Some studies modified CCI accordingly, as in a study on stroke patients⁷ and stable coronary artery disease.⁶ Another study purported that CCI might not be appropriate when using administrative data.²⁴

The results of this study using prospectively collected data are important because they not only show the impact of single comorbidities on in-hospital and 1 year outcomes in a large

population in real life, but also how the weighted comorbidities of CCI influenced the therapies received and, consequently, the outcomes of ACS patients. Furthermore, the validation of CCI showed that CCI seems to be an appropriate prognostic indicator for in-hospital as well as 1-year outcomes in ACS patients.

LIMITATIONS

Our study should be interpreted in the context of the following limitations: First, the weaknesses of AMIS Plus are common to all registries. Participation in the AMIS Plus registry is voluntary, the number of hospitals varied over the years and might not,

Table 3 Charlson weight of comorbidities and comorbidities as independent predictors of in-hospital mortality in patients hospitalised with acute coronary syndrome

Comorbidities	Charlson weight (points)	OR (95% CI) age and gender—adjusted	p Values
Past history of myocardial infarction	1	0.93 (0.82 to 1.05)	0.25
Heart failure	1	1.88 (1.57 to 2.25)	<0.001
Peripheral vascular disease	1	1.23 (1.03 to 1.48)	0.021
Cerebrovascular disease	1	1.26 (1.06 to 1.50)	0.009
Dementia	1	1.15 (0.90 to 1.47)	0.27
Chronic lung disease	1	1.18 (0.99 to 1.41)	0.07
Connective tissue disease	1	0.99 (0.64 to 1.51)	0.95
Peptic ulcer disease	1	0.98 (0.73 to 1.31)	0.87
Mild liver disease	1	1.72 (1.09 to 2.70)	0.019
Diabetes	1	1.35 (1.19 to 1.54)	<0.001
Diabetes with target organ damage	2	1.28 (1.04 to 1.58)	0.019
Hemiplegia	2	1.92 (1.28 to 5.87)	0.001
Moderate to severe renal disease	2	1.84 (1.60 to 2.11)	<0.001
Malignant neoplasm	2	1.29 (1.06 to 1.57)	0.012
Leukaemia	2	1.41 (0.69 to 2.88)	0.34
Lymphoma	2	0.75 (0.34 to 1.65)	0.48
Moderate to severe liver disease	3	1.82 (1.12 to 2.95)	0.016
Metastatic solid tumour	6	2.25 (1.60 to 3.19)	<0.001
AIDS (stage C)	6	None of the 47 patients died	




Figure 1 Receiver operating characteristic curve compared the discriminating ability of the Charlson Comorbidity Index (CCI) for predicting mortality if CCI was used alone (area=0.670; 95% CI 0.656 to 0.685), using CCI with age (area=0.756; 95% CI 0.743 to 0.768) and using all comorbidities, age and sex (area=0.761; 95% CI 0.748 to 0.773).




Figure 2 (A) In-hospital mortality compared with predicted mortality of patients admitted with acute coronary syndrome according to the Charlson Comorbidity Index (CCI) and age (n=29 620). (B) 1-year follow-up mortality compared with the predicted mortality of patients admitted with acute coronary syndrome according to the CCI and age (n=7066).

therefore, be entirely representative for all-comers to all hospitals in the country despite the permanent involvement of more than 70% of all hospitals treating ACS. Second, there was not an independent valuation of the comorbidities. Also, in addition to chronic diseases, acute, non-cardiac conditions could be concomitant with acute MI, and greatly impact the outcome of these patients.²⁵ Severe pneumonia, gastrointestinal bleeding, stroke and sepsis were associated with a marked increase in the risk of in-hospital mortality.²⁵ These conditions are not defined precisely enough in the CCI.

CCI was designed over 26 years ago, and although it has become the most widely used instrument to quantify chronic comorbidities for patients admitted to hospital for an acute major complaint, it was not designed specifically for patients with ACS. However, the present analysis is the largest multi-centric study focusing on the importance of chronic comorbid conditions among patients admitted with ACS, and shows that despite all limitations, CCI could be a useful, simple and adequate tool in prospective ACS cohort studies.

CONCLUSIONS

Comorbidities greatly influenced clinical presentation and the therapies received by patients admitted with ACS, and have a major impact on the short-term and mid-term outcomes of these patients. In this study, heart failure, diabetes, renal disease and metastatic tumours had a major impact on mortality.

Furthermore, CCI seems to be an appropriate prognostic indicator for in-hospital as well as 1-year outcomes in ACS patients.

Key messages

What is already known on this subject

The Charlson Comorbidity Index (CCI) was empirically developed 26 years ago to provide a way of quantifying the impact of comorbidities on survival, and has been used as a prognostic tool in acute coronary syndrome (ACS) populations. However, the impact of comorbidities on the presentation and treatment of these patients is insufficiently known as there has been little validation of CCI in terms of patients with ACS.

What this study adds

The results of this study are important because they not only show the impact of single comorbidities on in-hospital and 1-year-outcomes in a large real-life population, but also how the weighted comorbidities of CCI influence the therapies received, and consequently, the outcomes of ACS patients. Furthermore, this study shows that CCI indeed seems to be an appropriate prognostic indicator of in-hospital as well as 1-year outcomes in ACS patients.

Acknowledgements We gratefully thank our sponsors for their financial support. We also thank Jenny Piket for proofreading this manuscript.

Collaborators AMIS Plus participants 2002–2012: The authors would like to express their gratitude to the teams of the following hospitals (listed in alphabetical order with the names of the local principal investigators): Aarau, Kantonsspital (P Lessing); Affoltern am Albis, Bezirkspital (F Hess); Altdorf, Kantonsspital (R Simon); Altstätten, Kantonales Spital (PJ Hangartner); Baden, Kantonsspital (U Hufschmid); Basel, Universitätsspital Basel (P Hunziker/R Jeger); Basel, St. Claraspital (C Grädel/B Hornig); Bern, Beau-Site Klinik (A Schönfelder); Bern, Inselspital (S Windecker); Bern, Salem-Spital (T Rueff); Bern, Tiefenauspital (P Loretan); Biel, Spitalzentrum (H Schläpfer/C Roethlisberger); Brig-Glis, Oberwalliser Kreisspital (D Evéquo); Büsach, Spital (G Mang), Burgdorf; Regionalspital Emmental (D Rysler); Davos, Spital (G Niedermaier/W Kistler); Dornach, Spital (A Droll/T Hongler); Einsiedeln, Regionalspital (S Stäubli); Flawil, Spital (G Freiwald); Frauenfeld, Kantonsspital (HP Schmid); Fribourg, Hôpital cantonal (JC Stauffer/S Cook); Frutigen, Spital (K Bietenhard); Genève, Hôpitaux universitaires (JM Gaspoz/PF Keller); Glarus, Kantonsspital (W Wojtyna); Grenchen, Spital (B Oertli/R Schönberger); Herisau, Kantonales Spital (M Schmidli); Horgen, See Spital (B Federspiel/D Schröpfer); Interlaken, Spital (EM Weiss); Kreuzlingen, Herzzentrum Bodensee (K Weber); La Chaux-de-Fonds, Hôpital (H Zender); Lachen, Regionalspital (C Steffen/I Poepping); Langnau im Emmental, Regionalspital (A Hugli); Laufenburg, Gesundheitszentrum Fricktal (J Frei/E Koltai); Lugano, Cardiocentro Ticino (G Pedrazzini); Luzern, Kantonsspital (P Erne); Männedorf, Kreisspital (T Heimes); Mendrisio, Ospedale regionale (A Pagnamenta); Meyrin, Hôpital de la Tour (P Urban); Moutier, Hôpital du Jura bernoise (C Stettler);

Münsingen, Regionales Spital Zentrum (F Repond); Münsterlingen, Kantonsspital (F Widmer); Muri, Kreisspital für das Freiamt (C Heimgartner); Nyon, Group. Hosp. Ouest lémanique (R Polikar); Olten, Kantonsspital (S Bassetti); Rheinfelden, Gesundheitszentrum Fricktal (HU Iselin); Rorschach, Kantonales Spital (M Giger); Samedan, Spital Oberengadin (P Egger); Sarnen, Kantonsspital Obwalden (T Kaeslin); Schaffhausen, Kantonsspital (R Frey/A Fischer); Schlieren, Spital Limmattal (T Herren/B Caduff); Schwyz, Spital (P Eichhorn); Scuol, Ospital d'Engiadina Bassa (C Neumeier/G Flury); Sion, Hôpital du Valais (G Girod); Solothurn, Bürgerspital Solothurn (A Grêt/R Schönenberger/R Vogel); Stans, Kantonsspital Nidwalden (B Niggli); St. Gallen, Kantonsspital (H Rickli); Sursee, Luzerner Kantonsspital (S Yoon); Thun, Spital (U Stoller); Uster, Spital (E Bächli); Valenstadt, Kantonales Spital (D Schmidt/J Hellemann); Wetzikon, GZO Spital (M Graber/H Vontobel/U Eriksson); Winterthur, Kantonsspital (A Haller/T Fischer); Wolhusen, Luzerner Kantonsspital (M Peter); Zofingen, Spital (S Gasser); Zollikerberg, Spital (R Fatio); Zürich, Klinik im Park (O Bertel); Zürich, Universitätsspital Zürich (M Maggiorini); Zürich, Stadtspital Triemli (F Eberli); Zürich, Stadtspital Waid (M Fischler/S Christen/S Buchholz).

Contributors DR: conception and design, analysis and interpretation of data, drafting of the article. BS: analysis and interpretation of data, critical revision of manuscript. PU, FE, HR and OB: acquisition of data, critical revision of manuscript for intellectual content. MP: conception and design, critical revision of manuscript for intellectual content. PE: acquisition of data, conception and design, critical revision of manuscript for intellectual content.

Funding The AMIS Plus registry is funded by unrestricted grants from the Swiss Heart Foundation and from Abbot AG, Switzerland; Astra-Zeneca AG, Switzerland; Bayer (Schweiz) AG, Switzerland; Biotronik AG, Switzerland; Bristol-Myers Squibb AG, Switzerland; Daiichi-Sankyo/Lilly AG, Switzerland; Johnson & Johnson AG—Cordis Division, Switzerland; A Menarini AG, Switzerland; Merck Sharp & Dohme-Chibret AG, Switzerland; Medtronic AG, Switzerland; Pfizer AG, Switzerland; St. Jude Medical, Switzerland; Takeda Pharma AG, Switzerland. The sponsors did not play any role in the design, data collection, analysis, or interpretation of the registry.

Competing interests None.

Patient consent Obtained.

Ethics approval Supra-Regional Ethics Committee for Clinical Studies, the Swiss Board for Data Security and the Cantonal Ethics Commissions.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- Alexander KP, Newby LK, Cannon CP, *et al.* Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. *Circulation* 2007;115:2549–69.
- Alexander KP, Newby LK, Armstrong PW, *et al.* Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. *Circulation* 2007;115:2570–89.
- Boyd CM, Darer J, Boult C, *et al.* Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. *JAMA* 2005;294:716–24.
- Steg PG, Lopez-Sendon J, Lopez de Sa E, *et al.* External validity of clinical trials in acute myocardial infarction. *Arch Intern Med* 2007;167:68–73.
- Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. *N Engl J Med* 2004;351:2870–4.
- Sachdev M, Sun JL, Tsiatis AA, *et al.* The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. *J Am Coll Cardiol* 2004;43:576–82.
- Goldstein LB, Samsa GP, Matchar DB, *et al.* Charlson Index comorbidity adjustment for ischemic stroke outcome studies. *Stroke* 2004;35:1941–5.
- Friedl B, Bernardini J, Piraino B. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. *Am J Kidney Dis* 2001;37:337–42.
- Fassa AA, Urban P, Radovanovic D, *et al.* Impact of comorbidities on clinical presentation, management and outcome of patients with acute coronary syndrome. *Cardiovasc Med* 2010;13:155–61.
- Singh M, Rihal CS, Lennon RJ, *et al.* Influence of frailty and health status on outcomes in patients with coronary disease undergoing percutaneous revascularization. *Circ Cardiovasc Qual Outcomes* 2011;4:496–502.
- Boyd CM, Vollenweider D, Puhan MA. Informing evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseases. *PLoS ONE* 2012;7:e41601.

- 12 Charlson ME, Pompei P, Ales KL, *et al.* A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–83.
- 13 Quan H, Li B, Couris CM, *et al.* Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol* 2011;173:676–82.
- 14 Jeger RV, Radovanovic D, Hunziker PR, *et al.* Ten-year trends in the incidence and treatment of cardiogenic shock. *Ann Intern Med* 2008;149:618–26.
- 15 Radovanovic D, Erne P. AMIS Plus: Swiss registry of acute coronary syndrome. *Heart* 2010;96:917–21.
- 16 Radovanovic D, Urban P, Simon R, *et al.* Outcome of patients with acute coronary syndrome in hospitals of different sizes. A report from the AMIS Plus Registry. *Swiss Med Wkly* 2010;140:314–22.
- 17 Schoenenberger AW, Radovanovic D, Stauffer JC, *et al.* Age-related differences in the use of guideline-recommended medical and interventional therapies for acute coronary syndromes: a cohort study. *J Am Geriatr Soc* 2008;56:510–16.
- 18 Stauffer JC, Goy JJ, Duvoisin N, *et al.* Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus. *Swiss Med Wkly* 2012;142:w13573.
- 19 Thygesen K, Alpert JP, White HD, *et al.* Universal definition of myocardial infarction. *Eur Heart J* 2007;28:2525–38.
- 20 Steg PG, James SK, Atar D, *et al.* ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2012;33:2569–619.
- 21 Palau P, Nunez J, Sanchis J, *et al.* Differential prognostic effect of revascularization according to a simple comorbidity index in high-risk non-ST-segment elevation acute coronary syndrome. *Clin Cardiol* 2012;35:237–43.
- 22 Nunez JE, Nunez E, Facila L, *et al.* [Prognostic value of Charlson comorbidity index at 30 days and 1 year after acute myocardial infarction]. *Rev Esp Cardiol* 2004;57:842–9.
- 23 Schneeweiss S, Wang PS, Avorn J, *et al.* Improved comorbidity adjustment for predicting mortality in Medicare populations. *Health Serv Res* 2003;38:1103–20.
- 24 Grunau GL, Sheps S, Goldner EM, *et al.* Specific comorbidity risk adjustment was a better predictor of 5-year acute myocardial infarction mortality than general methods. *J Clin Epidemiol* 2006;59:274–80.
- 25 Lichtman JH, Spertus JA, Reid KJ, *et al.* Acute noncardiac conditions and in-hospital mortality in patients with acute myocardial infarction. *Circulation* 2007;116:1925–30.